Go Pro
→ A “bloodbath” Is Coming (From TradeSmith) (Ad)tc pixel Free JANX Stock Alerts

Janux Therapeutics (JANX) Short Interest Ratio & Short Volume

Janux Therapeutics logo
$16.47 -0.39 (-2.34%)
As of 01:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

Janux Therapeutics Short Interest Overview

As of August 31, 2026, Janux Therapeutics (JANX) had a short interest of 6.06 million shares sold short, representing 10.77% of the public float. This marks a -8.50% decrease in short interest since the prior report. The short interest ratio (days to cover) is 7.8, meaning it would take 7.8 days of the average trading volume of 1.10 million shares to cover all short positions.

Current Short Interest
6,063,535 shares
Previous Short Interest
6,626,696 shares
Change Vs. Previous Month
-8.50%
Dollar Volume Sold Short
$110.48 million
Short Interest Ratio
7.8 Days to Cover
Last Record Date
August 31, 2026
Outstanding Shares
61,137,000 shares
Short Percent of Float
10.77%
Today's Trading Volume
272,575 shares
Average Trading Volume
1,098,314 shares
Today's Volume Vs. Average
25%
Short Selling Janux Therapeutics?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Janux Therapeutics and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

JANX Short Interest Over Time

JANX Days to Cover Over Time

JANX Percentage of Float Shorted Over Time

Janux Therapeutics Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
8/31/20266,063,535 shares $110.48 million -8.5%10.8%7.81 $18.22
8/14/20266,626,696 shares $106.82 million +11.9%11.8%10.9 $16.12
7/31/20265,922,899 shares $89.85 million -8.2%10.5%7.74 $15.17
7/15/20266,454,019 shares $103.46 million -9.2%11.5%6.43 $16.03
6/30/20267,108,085 shares $109.18 million -6.7%12.7%3.59 $15.36
6/15/20267,615,380 shares $104.64 million -5.9%13.6%10.96 $13.74
5/29/20268,091,847 shares $118.06 million +3.4%14.4%6.83 $14.59
5/15/20267,827,096 shares $108.72 million -1.3%13.9%9.66 $13.89
4/30/20267,932,981 shares $114.00 million +6.6%14.1%7.4 $14.37
4/15/20267,440,069 shares $111.90 million -3.9%13.2%8.27 $15.04
3/31/20267,744,629 shares $107.65 million -22.7%13.8%5.51 $13.90
3/13/202610,020,131 shares $136.07 million +0.2%23.3%12.01 $13.58
2/27/20269,996,191 shares $136.05 million -1.5%23.3%12.52 $13.61
2/13/202610,144,569 shares $133.30 million -3.2%18.1%7.38 $13.14
1/30/202610,476,584 shares $143.63 million +10.9%24.7%5.58 $13.71
1/15/20269,444,405 shares $129.58 million +2.2%22.2%6.36 $13.72
12/31/20259,239,650 shares $127.51 million +24.9%21.8%3.5 $13.80
12/15/20257,395,136 shares $111.81 million -2.8%17.4%1.98 $15.12
11/28/20257,606,181 shares $260.85 million +6.7%17.9%6.91 $34.30
11/14/20257,131,951 shares $208.82 million +2.7%16.8%6.84 $29.28
10/31/20256,946,508 shares $199.43 million -18.9%16.4%5.8 $28.71
10/15/20258,560,000 shares $242.08 million -4.1%15.8%10.2 $28.28
9/30/20258,930,000 shares $218.25 million +7.6%16.4%11 $24.44
9/15/20258,300,000 shares $195.55 million +3.1%15.4%10.6 $23.56
8/31/20258,050,000 shares $182.90 million -0.4%14.9%10.5 $22.72
8/15/20258,080,000 shares $202.89 million -7.5%15.0%9.7 $25.11
7/31/20258,730,000 shares $209.61 million -9.5%16.0%9.9 $24.01
7/15/20259,650,000 shares $248.58 million -6.0%19.5%10.7 $25.76
6/30/202510,260,000 shares $237.01 million -3.3%20.7%10.7 $23.10
6/15/202510,610,000 shares $264.19 million -0.6%21.4%11.2 $24.90
5/31/202510,670,000 shares $252.99 million -7.6%21.6%10.9 $23.71
5/15/202511,550,000 shares $268.77 million +19.7%23.3%11.4 $23.27
4/30/20259,650,000 shares $320.38 million +3.3%19.5%10.2 $33.20
4/15/20259,340,000 shares $271.42 million -7.5%18.9%10.2 $29.06
3/31/202510,100,000 shares $272.70 million -3.8%20.4%10.1 $27.00
3/15/202510,500,000 shares $322.14 million +12.1%21.2%11.2 $30.68
2/28/20259,370,000 shares $308.18 million +3.1%19.1%8.7 $32.89
2/15/20259,090,000 shares $330.60 million +11.8%18.9%7.6 $36.37
1/31/20258,130,000 shares $353.49 million -4.9%17.0%7 $43.48
1/15/20258,550,000 shares $375.60 million +11.3%17.9%7.6 $43.93
Analyst nicknamed “The Prophet” issues new warning for America (Ad)

Whitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly 80% afterward. He also called the housing crisis and the collapse of Bear Stearns and Lehman Brothers before they happened. Now Tilson says the day after this year's midterm elections, America enters a period of economic change unlike anything seen in decades - and most investors are unprepared.tc pixel

See Whitney Tilson's full midterm election presentation now.
12/31/20247,680,000 shares $411.19 million +19.8%16.4%7.3 $53.54
12/15/20246,410,000 shares $391.72 million +43.1%13.6%6.8 $61.11
11/30/20244,480,000 shares $202.54 million +6.9%9.5%4.8 $45.21
11/15/20244,190,000 shares $204.30 million -2.8%9.8%6.6 $48.76
10/31/20244,310,000 shares $232.70 million -0.5%10.2%7.2 $53.99
10/15/20244,330,000 shares $228.36 million +25.1%10.7%7.5 $52.74
9/30/20243,460,000 shares $157.19 million +4.5%8.9%6.2 $45.43
9/15/20243,310,000 shares $165.53 million -0.3%8.6%5.6 $50.01
8/31/20243,320,000 shares $155.97 million +2.2%8.8%5.8 $46.98
8/15/20243,250,000 shares $134.94 million -11.2%8.6%4.8 $41.52
7/31/20243,660,000 shares $148.60 million -0.5%10.3%4.8 $40.60
7/15/20243,680,000 shares $159.97 million +3.1%10.4%4.6 $43.47
6/30/20243,570,000 shares $149.55 million +24.4%10.1%4 $41.89
6/15/20242,870,000 shares $120.54 million -4.0%8.1%3.4 $42.00
5/31/20242,990,000 shares $159.97 million +3.8%8.5%3.7 $53.50
5/15/20242,880,000 shares $136.74 million -12.7%8.5%2.5 $47.48
4/30/20243,300,000 shares $188.10 million -4.1%9.6%3.2 $57.00
4/15/20243,440,000 shares $178.40 million -8.3%10.0%3.8 $51.86
3/31/20243,750,000 shares $141.19 million +20.6%11.6%5.3 $37.65
3/15/20243,110,000 shares $122.69 million +7.2%9.6%4.6 $39.45
2/29/20242,900,000 shares $140.30 million +18.9%9.2%4.8 $48.38
2/15/20242,440,000 shares $23.18 million -0.4%8.6%6.6 $9.50
1/31/20242,450,000 shares $20.97 million -1.6%8.6%21.5 $8.56
1/15/20242,490,000 shares $25.27 million -0.8%8.8%20.6 $10.15
12/31/20232,510,000 shares $26.93 million +3.7%8.8%20.3 $10.73
12/15/20232,420,000 shares $25.10 million -5.1%8.5%20.5 $10.37
11/30/20232,550,000 shares $22.26 million +2.4%8.9%23.7 $8.73
11/15/20232,490,000 shares $21.86 million -4.6%8.7%23.5 $8.78
10/31/20232,610,000 shares $16.76 million -3.7%8.7%30.4 $6.42
10/15/20232,710,000 shares $23.69 million -5.9%9.1%31.8 $8.74
9/30/20232,880,000 shares $29.03 million -4.0%9.6%34.5 $10.08
9/15/20233,000,000 shares $29.61 million +1.4%10.0%31.7 $9.87
8/31/20232,960,000 shares $32.56 million +1.7%9.9%29.6 $11.00
8/15/20232,910,000 shares $34.92 million -3.0%9.7%26.4 $12.00
7/31/20233,000,000 shares $42 million +0.3%11.0%20 $14.00
7/15/20232,990,000 shares $37.26 million No Change11.8%20.8 $12.46
6/30/20232,990,000 shares $35.49 million -1.0%13.0%22.9 $11.87
6/15/20233,020,000 shares $39.56 million +4.9%13.1%24 $13.10
5/31/20232,880,000 shares $33.47 million -2.4%12.5%23.6 $11.62
5/15/20232,950,000 shares $35.49 million +0.3%12.8%26.6 $12.03
4/30/20232,940,000 shares $45.04 million +7.3%13.0%42.3 $15.32
4/15/20232,740,000 shares $40.11 million +4.6%12.1%35.7 $14.64
3/31/20232,620,000 shares $31.70 million -1.1%11.8%23.3 $12.10
3/15/20232,650,000 shares $35.64 million +3.9%11.9%22.6 $13.45
2/28/20232,550,000 shares $42.41 million +0.4%11.5%21.5 $16.63
2/15/20232,540,000 shares $43.21 million +8.6%11.4%21.7 $17.01
1/31/20232,340,000 shares $51.97 million +8.8%10.5%19.5 $22.21
1/15/20232,150,000 shares $44.23 million -13.7%9.7%17.5 $20.57
12/30/20222,490,000 shares $32.79 million +4.2%11.3%24.3 $13.17
12/15/20222,390,000 shares $30.35 million -9.5%10.8%30.7 $12.70
$20,000 gold before year end? (Ad)

President Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and America's $40 trillion national debt to a potential surge in gold prices, with some forecasts pointing to $10,000 or even $20,000 gold. Dr. David Eifrig, a 40-year market veteran and former Goldman Sachs Vice President, says an unusual plan involving Trump and two other top officials could fuel the biggest gold bull run in decades. Eifrig has shared his top gold pick tied to this developing story.tc pixel

Read the full gold report and see Eifrig's top pick now
11/30/20222,640,000 shares $36.01 million -2.2%12.0%36.8 $13.64
11/15/20222,700,000 shares $44.50 million -21.3%12.2%40.1 $16.48
10/31/20223,430,000 shares $62.01 million No Change15.6%58.7 $18.08
10/15/20223,430,000 shares $44.73 million -0.6%15.6%73.4 $13.04
9/30/20223,450,000 shares $46.71 million +1.8%15.7%63.5 $13.54
9/15/20223,390,000 shares $44.92 million +1.2%15.4%45.1 $13.25
8/31/20223,350,000 shares $36.25 million +3.1%15.2%45 $10.82
8/15/20223,250,000 shares $46.83 million -3.6%14.8%43.2 $14.41
7/31/20223,370,000 shares $41.86 million +0.9%15.4%39.1 $12.42
7/15/20223,340,000 shares $56.25 million +6.4%15.2%36.3 $16.84
6/30/20223,140,000 shares $38.34 million +3.3%14.3%34.8 $12.21
6/15/20223,040,000 shares $35.26 million +1.7%13.9%39.8 $11.60
5/31/20222,990,000 shares $33.28 million No Change13.7%39.2 $11.13
5/15/20222,990,000 shares $33.07 million +6.0%13.7%36.2 $11.06
4/30/20222,820,000 shares $27.75 million -5.1%12.9%36.4 $9.84
4/15/20222,970,000 shares $40.01 million -1.0%13.6%40 $13.47
3/31/20223,000,000 shares $43.02 million +3.1%13.7%38.1 $14.34
3/15/20222,910,000 shares $49.38 million +3.9%13.3%31.3 $16.97
2/28/20222,800,000 shares $48.38 million +2.9%12.8%26.5 $17.28
2/15/20222,720,000 shares $48.55 million -1.8%12.4%24.6 $17.85
1/31/20222,770,000 shares $42.19 million +3.8%12.4%25.2 $15.23
1/15/20222,670,000 shares $42.08 million +3.9%11.9%24.6 $15.76
12/31/20212,570,000 shares $50.71 million +6.6%11.5%25 $19.73
12/15/20212,410,000 shares $47.43 million +11.6%10.8%23.1 $19.68
11/30/20212,160,000 shares $38.40 million +9.6%10.2%17 $17.78
11/15/20211,970,000 shares $41.76 million +3.7%9.3%14.4 $21.20
10/29/20211,900,000 shares $46.27 million -2.6%9.0%12.6 $24.35
10/15/20211,950,000 shares $41.20 million +7.7%9.3%11.6 $21.13
9/30/20211,810,000 shares $39.15 million +37.1%8.6%8.3 $21.63

JANX Short Interest - Frequently Asked Questions

Short interest is the volume of Janux Therapeutics shares that have been sold short but have not yet been covered or closed out. As of August 31st, investors have sold 6,063,535 shares of JANX short. 10.77% of Janux Therapeutics' shares are currently sold short. Learn More on Janux Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. JANX shares currently have a short interest ratio of 7.8. Learn More on Janux Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.77% of Janux Therapeutics' floating shares are currently sold short.

Janux Therapeutics saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 6,063,535 shares, a decline of 8.5% from the previous total of 6,626,696 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

10.77% of Janux Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Janux Therapeutics: ACADIA Pharmaceuticals Inc. (7.66%), Celcuity, Inc. (25.20%), Edgewise Therapeutics, Inc. (10.93%), Dyne Therapeutics, Inc. (12.30%), Enliven Therapeutics, Inc. (12.10%), Relay Therapeutics, Inc. (20.93%), Legend Biotech Corporation Sponsored ADR (8.50%), Viking Therapeutics, Inc. (20.08%), Telix Pharmaceuticals Limited (0.08%), Iovance Biotherapeutics, Inc. (21.10%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($62.68 billion), Invesco QQQ ($47.06 billion), iShares Russell 2000 ETF ($23.54 billion), SPDR S&P Biotech ETF ($12.10 billion), Nebius Group N.V. ($9.34 billion), Western Digital Corporation ($8.96 billion), Financial Select Sector SPDR Fund ($8.16 billion), iShares 20+ Year Treasury Bond ETF ($7.98 billion), iShares iBoxx $ High Yield Corporate Bond ETF ($7.52 billion), and VanEck Semiconductor ETF ($7.39 billion). View all of the most shorted stocks.

Short selling JANX is an investing strategy that aims to generate trading profit from Janux Therapeutics as its price is falling. JANX shares are trading down $0.39 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Janux Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of JANX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including JANX, twice per month. The most recent reporting period available is August, 31 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like JANX:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

Short interest data for NASDAQ:JANX is sourced from the Financial Industry Regulatory Authority (FINRA), with the most recent report published on 9/10/2026. FINRA publishes updated short interest twice a month.
From Our Partners
“This is the Perfect Tech Stock”
Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...
Brownstone Research | Sponsoredtc pixel
Iran War: Why Is Trump Protecting THEM?
A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...
Banyan Hill Publishing | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel